October 27, 2026

Award recognizes outstanding efforts in type 1 diabetes research  

New York, Oct. 27, 2026—Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization, proudly announces Dr. Roy Beck as the recipient of the 2026 Mary Tyler Moore and S. Robert Levine, M.D., Excellence in Clinical Research Award for his leadership and achievements in T1D research.

The award was established in honor of Breakthrough T1D’s (formerly JDRF’s) International Chairman, Mary Tyler Moore and her husband, S. Robert Levine, M.D., for their extraordinary commitment to Breakthrough T1D’s mission. Established in 2004, this award recognizes leaders and innovators of outstanding clinical and translational T1D research. 

Dr. Beck is a physician and epidemiologist with more than 35 years of experience directing and coordinating multi-center clinical trials. He is the Medical Director of the JAEB Center for Health Research, a nonprofit clinical trials coordinating center in Tampa, Florida that he founded in 1993. Diabetes became a major focus of the JAEB Center and Dr. Beck’s research after one of his children developed T1D in the 1990s. During the last 25 years, he has directed the coordinating center for the National Institutes of Health (NIH) funded Diabetes Research in Children Network, the JDRF (now Breakthrough T1D) Continuous Glucose Monitor (CGM) Randomized Trial, the Pediatric Diabetes Consortium, the Type 1 Diabetes Exchange, and numerous CGM, automated insulin delivery system, and drug studies funded by NIH, Breakthrough T1D, the Helmsley Charitable Trust, and industry. Dr. Beck has been an author or co-author of more than 600 manuscripts in scientific journals.   

“Breakthrough T1D is pleased to honor Dr. Beck with this award and recognize his significant leadership and contributions that have moved the type 1 diabetes field forward,” said Breakthrough T1D Chief Scientific Officer Sanjoy Dutta, Ph.D. “His role in continuous glucose monitor and automated insulin delivery system research that were key to development of the devices available for T1D management today and has improved the lives of millions of people living with the condition. We are grateful for his ongoing work and counsel in the T1D research space.”

“Breakthrough T1D has played a key role in my career, and in fact, if not for their advocacy with Congress to establish and allocate funding for the Special Diabetes Program, I might never have gotten started on type 1 diabetes research,” Dr. Beck said. “During the last 25 years, Breakthrough T1D’s financial support and scientific engagement have been instrumental for the success of our projects.”

Breakthrough T1D research award recipients were recognized at a ceremony in Philadelphia earlier in October 2026.

About Breakthrough T1D, Formerly JDRF 
As the leading global type 1 diabetes research and advocacy organization, Breakthrough T1D helps make everyday life with type 1 diabetes better while driving toward cures. We do this by investing in the most promising research, advocating for progress by working with government to address issues that impact the T1D community, and helping educate and empower individuals facing this condition.

About Type 1 Diabetes (T1D) 
T1D is an autoimmune condition that causes the pancreas to make very little insulin or none at all. This leads to dependence on insulin therapy and the risk of short and long-term complications, which can include highs and lows in blood sugar; damage to the kidneys, eyes, nerves, and heart; and even death. Globally, it impacts 9.5 million people. Many believe T1D is only diagnosed in childhood and adolescence, but diagnosis in adulthood is common and accounts for nearly 50% of all T1D diagnoses. The onset of T1D has nothing to do with diet or lifestyle. While its causes are not yet entirely understood, scientists believe that both genetic factors and environmental triggers are involved. There is currently no cure for T1D.